Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Aliskiren
Drug: Enalapril

First Posted Date: 2010-06-28

Last Posted Date: 2016-03-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 208

Registration Number: NCT01151410

Locations: 🇹🇷
Novartis Investigative Site, Ankara, Turkey

Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Aliskiren (6.25/12.5/25 mg)
Drug: Aliskiren (37.5/75/150 mg)
Drug: Aliskiren (150/300/600 mg)

First Posted Date: 2010-06-24

Last Posted Date: 2015-10-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 267

Registration Number: NCT01150357

Locations: 🇹🇷
Novartis Investigative Site, Izmir, Turkey

Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients

Phase 3

Completed

Conditions: Liver Transplant Recipient

Interventions: Drug: Tacrolimus (reduced tacrolimus)
Drug: Tacrolimus (tacrolimus elimination)
Drug: Tacrolimus (tacrolimus control)
Drug: Everolimus (reduced tacrolimus)
Drug: Everolimus (tacrolimus elimination)
Drug: Corticosteroids

First Posted Date: 2010-06-24

Last Posted Date: 2018-11-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 284

Registration Number: NCT01150097

Locations: 🇬🇧
Novartis Investigative Site, Edinburgh, United Kingdom

Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)

Phase 4

Completed

Conditions: Age-related Macular Degeneration

Interventions: Drug: Ranibizumab 0.5 mg

First Posted Date: 2010-06-22

Last Posted Date: 2013-05-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 99

Registration Number: NCT01148511

Locations: 🇹🇷
Novartis Investigational Site, Ankara, Turkey
🇹🇷
Novartis Investigative Site, Konya, Turkey

Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)

Phase 2

Completed

Conditions: Colchicine Resistant/Intolerant Familial Mediterranean Fever

Interventions: Drug: Canakinumab

First Posted Date: 2010-06-22

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 15

Registration Number: NCT01148797

Locations: 🇮🇱
Meir Medical Center Kfar Saba, Kfar Saba, Israel
🇮🇱
Rambam Health Care Campus, Haifa, Israel
🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel

and more 2 locations

Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis

Phase 2

Terminated

Conditions: Dermatomyositis
Polymyositis

Interventions: Drug: Placebo
Drug: BAF312

First Posted Date: 2010-06-22

Last Posted Date: 2019-04-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT01148810

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

Phase 2

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Pazopanib
Drug: Sunitinib

First Posted Date: 2010-06-22

Last Posted Date: 2025-03-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 367

Registration Number: NCT01147822

Locations: 🇨🇳
Novartis Investigative Site, Taoyuan County, Taiwan

Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia

Phase 1

Completed

Conditions: Hyperlipoproteinemia

Interventions: Drug: Placebo
Drug: LCQ908

First Posted Date: 2010-06-17

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 8

Registration Number: NCT01146522

Locations: 🇨🇦
Novartis Investigative Site, Quebec, Canada

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

Phase 3

Completed

Conditions: Acromegaly

Interventions: Drug: octreotide LAR 30mg
Drug: Pasireotide
Drug: lanreotide ATG 120mg

First Posted Date: 2010-06-04

Last Posted Date: 2018-04-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 198

Registration Number: NCT01137682

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
Swedish Neuroscience Institute 550 17th Avenue, Suite 500, Seattle, Washington, United States

and more 2 locations

Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)

Phase 3

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: ranibizumab
Procedure: Laser

First Posted Date: 2010-06-03

Last Posted Date: 2014-10-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 241

Registration Number: NCT01135914

Locations: 🇨🇦
Memorial University Health Sciences Centre / Newfoundland Drive Medical Clinic, St-John's, Canada
🇨🇦
Dr.Michel Giunta Clinique Médicale, Sherbrooke, Quebec, Canada
🇨🇦
Saskatoon City Hospital / Spadina Clinic, Saskatoon, Saskatchewan, Canada

and more 17 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy